In the NIMH Schizophrenia Collaborative Study, patients were randomized to
receive one of four medications, either placebo or one of three different
anti-psychotic drugs. The protocol indicated subjects were to then be
evaluated at weeks 0, 1, 3, 6 to assess severity of illness; additionally
some measurements were made at weeks 2, 4, and 5.